Clinical

Articles

Twenty percent of patients with resectable hepatocellular carcinoma experienced significant tumor necrosis when treated with neoadjuvant cemiplimab-rwlc, according to data from a phase 2a open label.

Complete Pathological Responses Seen for Resectable HCC Treated With Neoadjuvant Cemiplimab

The addition of nivolumab to either chemotherapy or ipilimumab improved overall survival among patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, according to data from the phase 3 CheckMate-648 trial.

Addition of Nivolumab Improves OS in Patients with Unresectable, Advanced ESCC

Phase 2 trial data support the FDA breakthrough therapy designation for futibatinib in cholangiocarcinoma tumors positive for FGFR2 gene fusions and rearrangements.

Futibatinib Earns Breakthrough Therapy Designation for FGFR2+ Cholangiocarcinoma

The phase 3 CheckMate 577 trial is the first to show a checkpoint inhibitor in the adjuvant setting after trimodality therapy demonstrate a statistically significant and clinically meaningful improvement in disease-free survival in patients with resected esophageal and gastroesophageal junction cancer.

Adjuvant Nivolumab Improves DFS in Resected Esophageal/Gastroesophageal Junction Cancer

Based on positive overall and progression-free survival data from the phase 3 KEYNOTE-590 trial, pembrolizumab was approved by the FDA for use in patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma.

FDA Grants Approval to Pembrolizumab for the Treatment of Advanced Esophageal or GEJ Carcinoma

In order to properly utilize cancer therapies for personalized care, adequate molecular testing must be performed in patients who are eligible for these therapies, with this necessity becoming more and more prevalent in the treatment of gastrointestinal malignancies. 

Precision Medicine Takes Center Stage in GI Cancer

A selective internal radiation therapy from Boston Scientific Corporation, TheraSphere Y-90 Glass Microspheres, was granted FDA approval for the treatment of unresectable hepatocellular carcinoma. 

TheraSphere SIRT Received FDA Approval for Treatment of Unresectable HCC

ONCOLOGY® sat down with John L. Marshall, MD, chief of the Division of Hematology/Oncology at Medstar Georgetown University Hospital and director of the Ruesch Center for the Cure of Gastrointestinal Cancer as well as co-chair of the 6th Annual School of Gastrointestinal Oncology® (SOGO®), hosted by Physicians' Education Resource, LLC (PER®), to discuss how personalized approaches to treating various gastrointestinal malignancies has changed the therapy landscape.

Molecular Profiling and the Promise of Precision Medicine

Podcasts

Schilsky joined CancerNetwork®’s podcast to discuss ASCO’s Advance of the Year, the top priorities moving forward, and the COVID-19 pandemic.

Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

Videos

Richard Schilsky, MD, touched on the research driving ASCO to award “Advance of the Year” to molecular profiling in gastrointestinal cancers, and what the organization’s top priorities are in the near future.

Gastrointestinal Cancer | Topics